

(19) World Intellectual Property  
Organization

International Bureau

(43) International Publication Date  
12 September 2019 (12.09.2019)

WIPO | PCT

(10) International Publication Number  
**WO 2019/173551 A8**

## (51) International Patent Classification:

C07D 487/04 (2006.01) A61P 25/00 (2006.01)  
A61K 31/4985 (2006.01)

## (21) International Application Number:

PCT/US2019/021080

## (22) International Filing Date:

07 March 2019 (07.03.2019)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

62/639,846 07 March 2018 (07.03.2018) US

(71) Applicant: CYCLERION THERAPEUTICS, INC.  
[US/US]; 301 Binney Street, Cambridge, MA 02142 (US).(72) Inventors: NTI-ADDAE, Kwame, W.; c/o Ironwood  
Pharmaceuticals, Inc., 301 Binney Street, Cambridge, MA  
02142 (US). PRASAD, Leena, Kumari; c/o Ironwood  
Pharmaceuticals, Inc., 301 Binney Street, Cambridge, MA  
02142 (US). STORZ, Thomas; c/o Ironwood Pharmaceu-  
ticals, Inc., 301 Binney Street, Cambridge, MA 02142 (US).(74) Agent: DAVIS, Steven, G. et al.; McCarter & English,  
LLP, 265 Franklin Street, Boston, MA 02110 (US).(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,  
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,  
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,  
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,  
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

## Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

## Published:

- with international search report (Art. 21(3))

## (48) Date of publication of this corrected version:

11 June 2020 (11.06.2020)

## (15) Information about Correction:

see Notice of 11 June 2020 (11.06.2020)

(54) Title: CRYSTALLINE FORMS OF AN SGC STIMULATOR

(57) Abstract: The present disclosure relates to crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine, which are useful as a stimulator of soluble guanylate cyclase (sGC). The present disclosure also provides pharmaceutically acceptable compositions comprising the crystalline forms and methods of using said compositions in the treatment of various disorders.



WO 2019/173551 A8